Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 22;15(13):3293.
doi: 10.3390/cancers15133293.

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges

Jason van Leuven  1   2 , Simon Evans  3 , Ganessan Kichenadasse  1   2 , Neeltje Steeghs  4   5 , Billie Bonevski  1 , Gerd Mikus  1   6 , Madelé van Dyk  1   2
Affiliations

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges

Jason van Leuven et al. Cancers (Basel). .

Abstract

Precision medicine in oncology involves identifying the 'right drug', at the 'right dose', for the right person. Currently, many orally administered anti-cancer drugs, particularly kinase inhibitors (KIs), are prescribed at a standard fixed dose. Identifying the right dose remains one of the biggest challenges to optimal patient care. Recently the Precision Dosing Group established the Accurate Dosing of Anti-cancer Patient-centred Therapies (ADAPT) Program to address individualised dosing; thus, use existing anti-cancer drugs more safely and efficiently. In this paper, we outline our framework, based on the Medical Research Council (MRC) framework, with a simple 6-step process and strategies which have led to the successful implementation of the ADAPT program in South Australia. Implementation strategies in our 6-step process involve: (1) Evaluate the evidence and identify the cancer drugs: Literature review, shadowing other experts, establishing academic partnerships, adaptability/flexibility; (2) Establishment of analytical equipment for drug assays for clinical purposes: assessment for readiness, accreditation, feasibility, obtaining formal commitments, quality assurance to all stakeholders; (3) Clinical preparation and education: educational material, conducted educational meetings, involve opinion leaders, use of mass media, promote network weaving, conduct ongoing training; (4) Blood collection, sample preparation and analyses: goods received procedures, critical control points (transport time); (5) Interpret and release results with recommendations: facilitate the relay of clinical data to providers; (6) Clinical application: providing ongoing consultation, identify early adopters, identify, and prepare champions. These strategies were selected from the 73 implementation strategies outlined in the Expert Recommendations for Implementing Change (ERIC) study. The ADAPT program currently provides routine plasma concentrations for patients on several orally administered drugs in South Australia and is currently in its evaluation phase soon to be published. Our newly established framework could provide great potential and opportunities to advance individualised dosing of oral anti-cancer drugs in routine clinical care.

Keywords: implementation science; individualised dosing; oral anti-cancer drugs; personalised medicine; therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The cause, solution, and outcome of pharmacokinetic variability when a fixed dose is used, adapted from de Wit, 2015 [1].
Figure 2
Figure 2
The general framework for establishing programs for individualized dosing of cancer drugs.
Figure 3
Figure 3
The six-step process in establishing the ADAPT program.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. De Wit D., Guchelaar H.J., den Hartigh J., Gelderblom H., van Erp N.P. Individualized dosing of tyrosine kinase inhibitors: Are we there yet? Drug Discov. Today. 2015;20:18–36. doi: 10.1016/j.drudis.2014.09.007. - DOI - PubMed
    1. Klumpen H.J., Samer C.F., Mathijssen R.H., Schellens J.H., Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat. Rev. 2011;37:251–260. doi: 10.1016/j.ctrv.2010.08.006. - DOI - PubMed
    1. Mueller-Schoell A., Groenland S.L., Scherf-Clavel O., van Dyk M., Huisinga W., Michelet R., Jaehde U., Steeghs N., Huitema A.D.R., Kloft C. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur. J. Clin. Pharmacol. 2021;77:441–464. doi: 10.1007/s00228-020-03014-8. - DOI - PMC - PubMed
    1. Guerrero S., Lopez-Cortes A., Indacochea A., Garcia-Cardenas J.M., Zambrano A.K., Cabrera-Andrade A., Guevara-Ramirez P., Gonzalez D.A., Leone P.E., Paz Y.M.C. Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies. Sci. Rep. 2018;8:13978. doi: 10.1038/s41598-018-32264-x. - DOI - PMC - PubMed
    1. Westerdijk K., Desar I.M.E., Steeghs N., van der Graaf W.T.A., van Erp N.P., Dutch P., Oncology G. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br. J. Clin. Pharmacol. 2020;86:258–273. doi: 10.1111/bcp.14185. - DOI - PMC - PubMed

LinkOut - more resources